Two female patients received insulin degludec and liraglutide injection and developed allergic urticaria after 1 day and 2 days respectively. The drug was discontinued and other insulin was used for glucose-lowering therapy, and anti-allergy treatment was administered with dexamethasone, cetirizine and topical cream, then two patients' symptoms gradually improved. The results of the association between the two adverse drug reactions and insulin degludec and liraglutide injection were "probably relevant". According to the domestic and foreign literature, there were rare reports of allergic urticaria in diabetic patients using insulin degludec and liraglutide injection. By analyzing the clinical characteristics of the two cases of adverse drug reactions, the role of clinical pharmacists in judging allergens and participating in the adjustment of hypoglycemic regimens is explored, which provides reference for individualized clinical medication and safe medication.

1.Pappa E, Kostara C, Bairaktari E, et al. Effect of fixed-dose combination of insulin degludec and liraglutide on apoB-containing lipoprotein subclasses and HDL lipidome in type 2 diabetes[J]. J Diabetes Complications, 2022, 36(10): 108286. DOI: 10.1016/j.jdiacomp.2022.108286.

2.Novodvorský P, Haluzík M. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus[J]. Expert Opin Drug Saf, 2022, 21(3): 349-361. DOI: 10.1080/14740338.2021.1978974.

3.Fadini GP, Buzzetti R, Fittipaldi MR, et al. IDegLira for the real-world treatment of type 2 diabetes in Italy: protocol and interim results from the REX observational study[J]. Diabetes Ther, 2022, 13(8):1483-1497. DOI: 10.1007/s13300-022-01287-z.

4.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

5.Tibaldi J, Mercado ME, Strong J. How effective is the fixedratio combination of insulin degludec and liraglutide (IDegLira) in different patient populations, and when should it be used in clinical practice[J]. Clin Diabetes, 2020, 38(4): 339-347. DOI: 10.2337/cd20-0014.

6.Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events[J]. J Am Acad Dermatol, 2020, 83(5): 1255-1268. DOI: 10.1016/j.jaad.2020.03.132.

7.Romano I, Serra R. Use of IDegLira to intensify, simplify, and increase appropriateness of type 2 diabetes therapy: a real-life experience[J]. Diabetes Ther, 2024, 15(1): 145-154. DOI: 10.1007/s13300-023-01489-z.

8.Kolb H, Kempf K, Röhling M, et al. Insulin:too much of a good thing is bad[J]. BMC Med, 2020, 18(1): 224. DOI: 10.1186/s12916-020-01688-6.

9.Lijesh KU, Gupta RD, Senthilraja M, et al. Exogenous recombinant human insulin-induced severe hypersensitivity reaction precipitating hyperglycemic crisis: a clinical conundrum[J]. J Family Med Prim Care, 2020, 9(8): 4470-4472. DOI: 10.4103/jfmpc.jfmpc_148_20.

10.陶依然, 黄琳, 李理总, 等. 非动物源性胰岛素所致过敏反应的文献汇总与分析[J]. 临床药物治疗杂志, 2021, 19(5): 21-25. [Tao YR, Huang L, Li LZ, et al. Literature analysis on allergic reaction caused by non-animal derived insulin[J]. Clinical Medication Journal, 2021, 19(5): 21-25.] DOI: 10.3969/j.issn.1672-3384. 2021.05.005.

11.郑晓辉, 赵振营, 杨晨, 等. 谷赖胰岛素治疗1例多种胰岛素过敏病例分析[J]. 药物流行病学杂志, 2020, 29(3): 190-192. [Zheng XH, Zhao ZY, Yang C, et al. Analysis of insulin glulisine in one patient allergic to various insulins[J]. Chinese Journal of Pharmacoepidemiology, 2020, 29(3): 190-192.] DOI: 10.19960/j.cnki.issn1005-0698.2020.03.010.

12.Bouzas C, Pastor R, Garcia S, et al. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome[J]. Biomed Pharmacother, 2023, 161: 114561. DOI: 10.1016/j.biopha.2023.114561.

13.Kyriakos G, Diamantis E, Memi E, et al. An uncommon case of dulaglutide-related morbilliform drug eruption[J]. Cureus, 2022, 14(1): e21536. DOI: 10.7759/cureus.21536.

14.Liu X, Zhai A, Zhang B. A case report of severe adverse reaction of exenatide: anaphylactic shock[J]. Medicine (Baltimore), 2022, 101(39): e30805. DOI: 10.1097/MD.0000000000030805.

15.Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?[J]. Curr Atheroscler Rep, 2022, 24(11): 867-884. DOI: 10.1007/s11883-022-01062-2.

16.Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity[J]. Adv Exp Med Biol, 2021, 1307: 171-192. DOI: 10.1007/5584_2020_496.

17.金思彤, 吴乃君, 邹英楠, 等. 利拉鲁肽脱敏治疗1例 [J].中国现代医学杂志, 2019, 29(8): 127-128. [Jin ST, Wu NJ, Zou YN, et al. One case of treated with liraglutide desensitization[J]. China Journal of Modern Medicine, 2019, 29(8): 127-128.] DOI: 10.3969/j.issn.1005-8982. 2019. 08.029.

18.Shamriz O, NaserEddin A, Mosenzon O, et al. Allergic reaction to exenatide and lixisenatide but not to liraglutide: unveiling anaphylaxis to glucagon-like peptide 1 receptor agonists[J]. Diabetes Care, 2019, 42(9): e141-e142. DOI: 10.2337/dc19-0720.

19.Egede LE, Bogdanov A, Fischer L, et al. Glycemic control among patients newly prescribed IDegLira across prior therapy group in US real-world practice[J]. Diabetes Ther, 2020, 11(7): 1579-1589. DOI: 10.1007/s13300-020-00850-w.

20.王晋星一, 胡涵帅, 李卫卫, 等. 临床药师对1例胰岛素制剂过敏的糖尿病患者降糖方案的个体化设计 [J]. 海峡药学, 2022, 34(2): 152-154. [Wang JXY, Hu HS, Li WW, et al. Participation of clinical pharmacist in hypoglycemic program for one case of diabetes allergic to insulin preparation[J]. Strait Pharmaceutical Journal, 2022, 34(2): 152-154.] DOI: 10.3969/j.issn.1006-3765. 2022.02.043.

21.唐彦, 王嘉麟, 周婧雅, 等. 1例胰岛素过敏合并胰岛素自身抗体阳性的暴发性1型糖尿病患者的药学监护 [J]. 中国药物警戒, 2022, 19(12): 1376-1379. [Tang Y, Wang JL, Zhou JY, et al. Pharmaceutical care for a case of fulminant type 1 diabetes with insulin allergy and positive insulin autoantibodies[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1376-1379.] DOI: 10.19803/j.1672-8629. 20210758.

22.Shuster S, Borici-Mazi R, Awad S, et al. Rapid desensitization with intravenous insulin in a patient with diabetic ketoacidosis and insulin allergy[J]. AACE Clin Case Rep, 2020, 6(4): e147-e150. DOI: 10.4158/ACCR-2019-0562.

23.李理总, 陶依然, 宋荣景, 等. 胰岛素过敏患者脱敏治疗文献分析[J]. 临床药物治疗杂志, 2021, 19(5): 26-31. [Li LZ, Tao YR, Song RJ, et al. Literature analysis on desensitization treatment for patients with insulin allergy[J]. Clinical Medication Journal, 2021, 19(5): 26-31.] DOI: 10.3969/j.issn.1672-3384.2021.05.006.